Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA Case Filings Drop 32%, But Still High Compared To Last Decade

Executive Summary

Lex Machina reports that 316 ANDA cases were filed in 2016 compared to 468 in 2015; number of inter partes review petitions filed on Orange Book patents has declined since 2015.

You may also be interested in...



Ampyra, Patents, And The Perils Of Letting PTAB Get Your Hopes Up

In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.

ANDA Litigation Soars In 2014-2015; Patent Office Petitions Also Jump

Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.

US FDA’s PANDA Policy Could Pose Legal Problems For Biosimilars, Attorney Says

Agency’s apparent intellectual exercise in treating pre-Hatch-Waxman ANDAs as NDAs could expose biosimilars to liability, Teva deputy general counsel notes at FDLI conference.

Topics

Related Companies

UsernamePublicRestriction

Register

PS120519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel